Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of “Hold” by Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have earned a consensus recommendation of “Hold” from the seventeen research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $37.67.

SAGE has been the topic of several analyst reports. TD Cowen lowered their price target on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Canaccord Genuity Group reduced their price target on shares of Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating on the stock in a research report on Friday, April 26th. Wedbush restated a “neutral” rating and set a $24.00 target price on shares of Sage Therapeutics in a research report on Wednesday, April 17th. Truist Financial cut their target price on shares of Sage Therapeutics from $22.00 to $18.00 and set a “hold” rating on the stock in a research report on Friday, April 26th. Finally, StockNews.com raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 27th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. RTW Investments LP bought a new position in Sage Therapeutics in the third quarter valued at about $105,976,000. Jacobs Levy Equity Management Inc. bought a new position in Sage Therapeutics in the third quarter valued at about $8,052,000. Rafferty Asset Management LLC grew its position in Sage Therapeutics by 197.1% in the third quarter. Rafferty Asset Management LLC now owns 411,904 shares of the biopharmaceutical company’s stock valued at $8,477,000 after acquiring an additional 273,257 shares during the last quarter. Hudson Bay Capital Management LP grew its position in Sage Therapeutics by 1,733.3% in the third quarter. Hudson Bay Capital Management LP now owns 275,000 shares of the biopharmaceutical company’s stock valued at $5,660,000 after acquiring an additional 260,000 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in Sage Therapeutics by 3.3% in the third quarter. Wellington Management Group LLP now owns 6,572,260 shares of the biopharmaceutical company’s stock valued at $135,257,000 after acquiring an additional 208,630 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Down 4.9 %

NASDAQ SAGE opened at $13.25 on Tuesday. Sage Therapeutics has a 12-month low of $10.92 and a 12-month high of $59.99. The stock has a market capitalization of $797.39 million, a PE ratio of -1.58 and a beta of 0.91. The company has a 50 day moving average price of $17.50 and a two-hundred day moving average price of $20.41.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The company had revenue of $7.90 million for the quarter, compared to the consensus estimate of $5.26 million. During the same period last year, the firm posted ($2.46) EPS. The company’s revenue was up 139.4% compared to the same quarter last year. As a group, equities analysts anticipate that Sage Therapeutics will post -6.53 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.